Global clinical trial technology company Clinical Ink announced that it has deployed an industry-leading 500 unique eCOA scales and assessments in 82 languages. eCOA, or electronic clinical outcome assessment, instruments play a critical role in clinical trial conduct and are used in a variety of ways, from screening for inclusion to use as a primary endpoint.
The complex eCOA scales and assessments solutions Clinical Ink is offering include the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Vineland-3, Bayley-III, and others that have never been implemented effectively in an electronic format. The company’s Lunexis platform supports administering complex rating instruments and enables audio and video collection that facilitate rater review to ensure inter- and intra-rater reliability.
“A significant share of the clinical trials industry is still relying on paper and pencil cognitive tests when electronic versions are available—versions that support not only better data quality but reduced timelines and cost,” said Clinical Ink CEO Ed Seguine. “Our complex eCOA scales and assessment implementations represent a new standard of trial execution simplicity and efficiency.”
A neuropsychologist with firsthand experience with Clinical Ink’s customized complex scales and assessments recently said, “This project was a huge undertaking, and I was sure I was going to find at least a couple errors in that data generated by Clinical Ink’s eCOA. There were no errors. They eliminated the inevitable human errors that occur when using traditional solutions requiring transcription and manual grading.”
Clinical Ink implements and deploys clinician-reported scales and assessments for even the most complex eCOA solutions, streamlining workflows and producing clean, complete data for challenging studies. Clinical Ink’s real-time prompts and edit checks help provide complete data sets, from which complex scoring can be generated automatically. Data can be monitored as it comes in and queried as appropriate.
See the original press release here.